The Wegovy Single-Dose Pen: Clearing Up the Biggest Misconception

The misconception worth correcting first: 'single-dose' doesn't mean a one-off injection

A common misread of the name is that this pen delivers a single course of treatment, as if one injection is the whole plan. It isn't. 'Single-dose' refers to the pen's design: each device holds exactly one 7.2 mg dose, used once a week, then discarded. The previous format required three separate 2.4 mg pens administered in a single week to reach the same total. The new pen simplifies that considerably.

The broader treatment structure stays the same. You still begin semaglutide at 0.25 mg, working through 0.5 mg, 1.0 mg, 1.7 mg and 2.4 mg before any prescriber would consider moving to 7.2 mg. Rushing that schedule isn't a shortcut, the titration exists because the gastrointestinal side effects of semaglutide (nausea, loose stools, indigestion) are dose-related, and stepping up gradually gives your system time to adjust. If you want to understand exactly how each strength is administered and what to expect at each stage, the Wegovy pen dose guide covers how the device delivers each level in detail. If you want the full picture of how the dose ladder unfolds, the Wegovy dose schedule page covers each step in detail.

The MHRA's approval confirmed one more important boundary: the 7.2 mg single-dose pen is licensed for adults with a BMI of 30 or above only. The lower 27–29.9 threshold (which applies to the standard Wegovy pen when a weight-related condition is also present) does not extend to this higher-dose device. A prescriber must assess this at every stage, not just at the start of treatment.

What the pen itself is designed to do

The device has three features that distinguish it from earlier Wegovy pens. First, the dose is pre-set: there is no dial or adjustment, removing any risk of selecting the wrong strength. Second, the needle is covered before and after use, which many patients find easier to manage, particularly those who found the earlier format fiddly. Third, the pen locks automatically once the injection is complete, preventing accidental re-use.

Storage follows the same rules as all Wegovy pens: keep it refrigerated between 2°C and 8°C. Most people simply slot it in the fridge door alongside their other weekly staples and take it out a few minutes before injecting so the liquid reaches room temperature. If you need to travel or store it outside the fridge temporarily, the exact permitted window is stated in the Patient Information Leaflet, always follow that rather than any general guidance. The guide to using the Wegovy single-dose pen walks through preparation and injection technique step by step.

The standard four-dose pen remains available for patients earlier in the titration process. The two formats are not interchangeable mid-week; your prescriber decides which is appropriate based on where you are in treatment.

Clinical results at 7.2 mg and what they mean in practice

The approval of this pen was supported by trial evidence showing around 20.7% average weight loss over 72 weeks at the 7.2 mg dose, bringing semaglutide's results closer to those seen with tirzepatide at its highest dose. For context, the 2.4 mg maintenance dose studied in the STEP 1 trial produced roughly 15% average weight loss over 68 weeks, as published in the New England Journal of Medicine. The 7.2 mg data suggests meaningful additional benefit, though individual results vary and are never guaranteed.

What this doesn't change is the principle that weight-loss medicines work best alongside dietary changes and increased activity. The pen handles one part of the picture. Your prescriber, and the clinical review that happens before every repeat order at nume, handles the rest. If you're exploring whether semaglutide is the right choice at all, the Wegovy overview sets out the full licensed indication, eligibility criteria and how it compares to other options.

Cost is a practical consideration too. Private semaglutide treatment at higher doses carries a higher price per pen, and the total monthly outlay shifts as you move up the titration ladder. The Wegovy pricing context page explains what legitimate treatment costs include and why the cheapest listing is rarely the safest starting point for a prescription medicine. The MHRA has warned publicly about counterfeit weight-loss pens sold online; the MHRA's Yellow Card scheme lets you report any suspect seller or product.

Who can access the single-dose pen and how the process works

Semaglutide at any dose is a prescription-only medicine. That means no pharmacy (online or otherwise) may supply it without a valid prescription issued following clinical assessment. The MHRA confirmed this when it approved the 7.2 mg pen: the indication requires a BMI of 30 or above, treatment within a structured weight management programme, and prescriber oversight throughout.

On the NHS, semaglutide for weight management is available through specialist services under NICE guidance (TA875), but waiting lists are commonly long and criteria are tightly defined. Private treatment offers an alternative for people who don't qualify for an NHS referral or don't want to wait, provided they meet the licensed eligibility criteria. You can verify any online pharmacy on the GPhC's public register before trusting them with a prescription medicine, this is the simplest check available and takes under a minute.

At nume, a GPhC-registered Independent Prescriber reviews every consultation personally. If 7.2 mg is the right point in your treatment and the clinical picture supports it, starting a free consultation is the first step. Specific dose availability is confirmed during that process, not before, because clinical suitability, not stock, drives the decision.